Mass General Brigham, Inc recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
101 MERRIMAC STREET BOSTON, MA 02114
As of the latest 13F report, the guru’s equity portfolio contained 3 stocks valued at a total of $192.00Mil. The top holdings were IVV(55.93%), AGG(39.75%), and COIN(4.32%).
According to GuruFocus data, these were Mass General Brigham, Inc’s top five trades of the quarter.
iShares Core S&P 500 ETF
Mass General Brigham, Inc reduced their investment in ARCA:IVV by 19,475 shares. The trade had a 3.45% impact on the equity portfolio. During the quarter, the stock traded for an average price of $397.41.
On 10/19/2022, iShares Core S&P 500 ETF traded for a price of $368.255 per share and a market cap of $277.42Bil. The stock has returned -17.27% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, iShares Core S&P 500 ETF has a price-earnings ratio of 17.81 and a price-book ratio of 3.35.
iShares Core U.S. Aggregate Bond ETF
Mass General Brigham, Inc reduced their investment in ARCA:AGG by 58,965 shares. The trade had a 2.8% impact on the equity portfolio. During the quarter, the stock traded for an average price of $100.7.
On 10/19/2022, iShares Core U.S. Aggregate Bond ETF traded for a price of $94.26 per share and a market cap of $76.05Bil. The stock has returned -15.75% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
Jounce Therapeutics Inc
The guru sold out of their 20,957-share investment in NAS:JNCE. Previously, the stock had a 0% weight in the equity portfolio. Shares traded for an average price of $4.89 during the quarter.
On 10/19/2022, Jounce Therapeutics Inc traded for a price of $1.98 per share and a market cap of $101.27Mil. The stock has returned -77.09% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Jounce Therapeutics Inc has a price-book ratio of 0.65, a EV-to-Ebitda ratio of 0.26 and a price-sales ratio of 3.73.
The price-to-GF Value ratio is 0.75, earning the stock a GF Value rank of 7.
Airbnb Inc
The guru sold out of their 1,932-share investment in NAS:ABNB. Previously, the stock had a 0% weight in the equity portfolio. Shares traded for an average price of $130.8 during the quarter.
On 10/19/2022, Airbnb Inc traded for a price of $116.16 per share and a market cap of $74.45Bil. The stock has returned -31.81% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Airbnb Inc has a price-earnings ratio of 63.61, a price-book ratio of 14.19, a EV-to-Ebitda ratio of 45.40 and a price-sales ratio of 10.43.
DocuSign Inc
The guru sold out of their 3,864-share investment in NAS:DOCU. Previously, the stock had a 0% weight in the equity portfolio. Shares traded for an average price of $114.94 during the quarter.
On 10/19/2022, DocuSign Inc traded for a price of $46.26 per share and a market cap of $9.31Bil. The stock has returned -83.00% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, DocuSign Inc has a price-book ratio of 22.57, a EV-to-Ebitda ratio of -1241.00 and a price-sales ratio of 3.89.
The price-to-GF Value ratio is 0.16, earning the stock a GF Value rank of 2.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
